[Form 4] Beam Therapeutics Inc. Insider Trading Activity

Rhea-AI Filing Summary

Beam Therapeutics insider Christine Bellon, Chief Legal Officer, reported an automatic sale of 373 shares of common stock on 10/01/2025 at a price of $24.53 per share. The sale was made to satisfy tax withholding obligations triggered by the vesting of restricted stock units granted on 9/30/2021. The shares were sold under a Rule 10b5-1 trading plan adopted by the reporting person on 5/19/2023. After the transaction, the reporting person beneficially owned 116,921 shares.

Positive

• Prearranged Rule 10b5-1 plan in place (adopted 5/19/2023) which clarifies trade intent
• Sale explicitly tied to tax withholding for RSU vesting on 9/30/2021, indicating routine compensation activity

Negative

• None.

Insights

Corporate Governance Specialist

Insider sale was a tax-withholding disposition under a prearranged plan.

The Form 4 shows an automatic disposition of 373 shares on 10/01/2025 executed under a Rule 10b5-1 plan adopted on 5/19/2023. This indicates the sale was preplanned and not a discretionary trade by the officer.

Because the filing states the sale covered tax withholding for RSU vesting on 9/30/2021, the transaction is routine compensation-related activity rather than an opportunistic liquidity move.

Compensation & Tax Analyst

Sale amount corresponds to tax withholding for vested restricted stock units.

The explanatory note explicitly ties the sale to withholding obligations from RSUs granted under the 2019 Equity Incentive Plan. The executed sale price was $24.53 per share, implying the employer or reporting person used share withholding via sale to meet tax liabilities.

This is a common mechanism to satisfy tax on equity compensation and does not alter disclosed post-transaction ownership of 116,921 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Bellon Christine

(Last) (First) (Middle)

C/O BEAM THERAPEUTICS INC.,

238 MAIN STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2025		S(1)		373	D	$24.53	116,921	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on September 30, 2021. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023.

	By: /s/ Christine Bellon	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did BEAM insider Christine Bellon sell?

She sold 373 shares of Beam Therapeutics common stock on 10/01/2025 at $24.53 per share.

Why were the shares sold by the BEAM reporting person?

The sale was made to cover tax withholding obligations from the vesting of restricted stock units granted on 9/30/2021.

Was the trade discretionary or preplanned for BEAM insider trades?

The transaction was executed under a Rule 10b5-1 trading plan adopted on 5/19/2023, indicating it was prearranged.

How many BEAM shares does Christine Bellon own after the sale?

The filing reports she beneficially owns 116,921 shares following the transaction.

Which equity plan governed the vested RSUs that triggered the sale?

The RSUs were granted under the Beam Therapeutics Inc. 2019 Equity Incentive Plan.